Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taha Merghoub

Showing results (11-20 of 216) with videos related to

Pageof 22
Sort By:
Cancer Cell|April 11, 2018
Emerging Concepts for Immune Checkpoint Blockade-Based Combination TherapiesRoberta Zappasodi, Taha Merghoub, Jedd D Wolchok
Current Hematologic Malignancy Reports|August 31, 2018
Strategies for Predicting Response to Checkpoint InhibitorsRoberta Zappasodi, Jedd D Wolchok, Taha Merghoub
Current Hematologic Malignancy Reports|November 9, 2018
Correction to: Strategies for Predicting Response to Checkpoint InhibitorsRoberta Zappasodi, Jedd D Wolchok, Taha Merghoub
Oncoimmunology|March 26, 2013
Myeloid-derived suppressor sells and the efficacy of CD8<sup>+</sup> T-cell immunotherapyAlexander M Lesokhin, Taha Merghoub, Jedd D Wolchok
Annals of Translational Medicine|September 21, 2020
Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targetsLuis F Campesato, Chien-Huan Weng, Taha Merghoub
Methods in Enzymology|January 18, 2020
In vitro assays for effector T cell functions and activity of immunomodulatory antibodiesRoberta Zappasodi, Sadna Budhu, Mohsen Abu-Akeel, et al.
Cancer Cell|April 5, 2024
Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effectsLukas Kraehenbuehl, Jedd D Wolchok, Taha Merghoub, et al.
Frontiers in Immunology|April 20, 2019
Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal EffectNathan Suek, Luis Felipe Campesato, Taha Merghoub, et al.
Cell|March 4, 2014
Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activationNora Pencheva, Colin G Buss, Jessica Posada, et al.
Ebiomedicine|May 24, 2016
Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumorsRikke B Holmgaard, Dmitriy Zamarin, Alexander Lesokhin, et al.
Pageof 22

Showing results (11-20 of 216) with videos related to

Sort By:
Pageof 22
Cancer Cell|April 11, 2018
Emerging Concepts for Immune Checkpoint Blockade-Based Combination TherapiesRoberta Zappasodi, Taha Merghoub, Jedd D Wolchok
Current Hematologic Malignancy Reports|August 31, 2018
Strategies for Predicting Response to Checkpoint InhibitorsRoberta Zappasodi, Jedd D Wolchok, Taha Merghoub
Current Hematologic Malignancy Reports|November 9, 2018
Correction to: Strategies for Predicting Response to Checkpoint InhibitorsRoberta Zappasodi, Jedd D Wolchok, Taha Merghoub
Oncoimmunology|March 26, 2013
Myeloid-derived suppressor sells and the efficacy of CD8<sup>+</sup> T-cell immunotherapyAlexander M Lesokhin, Taha Merghoub, Jedd D Wolchok
Annals of Translational Medicine|September 21, 2020
Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targetsLuis F Campesato, Chien-Huan Weng, Taha Merghoub
Methods in Enzymology|January 18, 2020
In vitro assays for effector T cell functions and activity of immunomodulatory antibodiesRoberta Zappasodi, Sadna Budhu, Mohsen Abu-Akeel, et al.
Cancer Cell|April 5, 2024
Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effectsLukas Kraehenbuehl, Jedd D Wolchok, Taha Merghoub, et al.
Frontiers in Immunology|April 20, 2019
Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal EffectNathan Suek, Luis Felipe Campesato, Taha Merghoub, et al.
Cell|March 4, 2014
Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activationNora Pencheva, Colin G Buss, Jessica Posada, et al.
Ebiomedicine|May 24, 2016
Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumorsRikke B Holmgaard, Dmitriy Zamarin, Alexander Lesokhin, et al.
Pageof 22